Johan van der Lei

Johan van der Lei

Auto-generated profile, based on publicly available information

Johan van der Lei

Department of Medical Informatics Erasmus University Medical Center Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
VVVera E. Valkhoff
Vera E. Valkhoff
PCPreciosa M. Coloma
Preciosa M. Coloma
GMGwen M.C. Masclee
Gwen M.C. Masclee
Rosa GiniRosa Gini
Rosa Gini
FIFrancesco Innocenti
Francesco Innocenti
GTGianluca Trifirò
Gianluca Trifirò

17 May 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
NLNienke Legdeur
Nienke Legdeur
SLSven J. van der Lee
Sven J. van der Lee
MWMarcel de Wilde
Marcel de Wilde
JLJohan van der Lei
Johan van der Lei
Majon MullerMajon Muller
Majon Muller
PVPieter Jelle Visser
Pieter Jelle Visser
There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident dementia in different age groups in a large primary care database. We included 442,428 individuals without dementia aged ≥ 65 years from the longitudinal primary care Integrated Primary Care Information (IPCI) database. We determined in 6 age groups (from 65–70 to ≥ 90 years) the risk of hypertension, diabetes mellitus, dyslipidemia, stroke, myocardial infarction, heart failure, and atrial fibrillation for all-cause dementia using incidence rate ratios, Cox regression, and Fine and Gray regression models. The mean age at inclusion of the total study sample was 72.4 years, 45.7% of the participants were male, and median follow-up was 3.6 years. During 1.4 million person-years of follow-up, 13,511 individuals were diagnosed with dementia. The risk for dementia decreased with increasing age for all risk factors and was no longer significant in individuals aged ≥ 90 years. Adjusting for mortality as a competing risk did not change the results. We conclude that vascular disorders are no longer a risk factor for dementia at high age. Possible explanations include selective survival of individuals who are less susceptible to the negative consequences of vascular disorders and differences in follow-up time between individuals with and without a vascular disorder. Future research should focus on the identification of other risk factors than vascular disorders, for example, genetic or inflammatory processes, that can potentially explain the strong age-related increase in dementia risk.

21 January 2014 in Drug Safety
Verified
Journal Article
Closed access
PDF file
ECEU-ADR consortium
EU-ADR consortium
CFCarmen Ferrajolo
Carmen Ferrajolo
PCPreciosa M. Coloma
Preciosa M. Coloma
KVKatia M. C. Verhamme
Katia M. C. Verhamme
MSMartijn J. Schuemie
Martijn J. Schuemie
MSMiriam C. J. M. Sturkenboom
Miriam C. J. M. Sturkenboom

16 February 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SBSandra de Bie
Sandra de Bie
PCPreciosa M. Coloma
Preciosa M. Coloma
CFCarmen Ferrajolo
Carmen Ferrajolo
KVKatia M. C. Verhamme
Katia M. C. Verhamme
GTGianluca Trifirò
Gianluca Trifirò
OCon behalf of the EU‐ADR consortium
on behalf of the EU‐ADR consortium
Aim: Electronic healthcare record (EHR)‐based surveillance systems are increasingly being developed to support early detection of safety signals. It is unknown what the power of such a system is for surveillance among children and adolescents. In this paper we provide estimates of the number and classes of drugs, and incidence rates (IRs) of events, that can be monitored in children and adolescents (0–18 years).Methods: Data were obtained from seven population‐based EHR databases in Denmark, Italy, and the Netherlands during the period 1996–2010. We estimated the number of drugs for which specific adverse events can be monitored as a function of actual drug use, minimally detectable relative risk (RR) and IRs for 10 events.Results: The population comprised 4 838 146 individuals (25 575 132 person years (PYs)), who were prescribed 2170 drugs (1 610 631 PYs drug‐exposure). Half of the total drug‐exposure in PYs was covered by only 18 drugs (0.8%). For a relatively frequent event like upper gastrointestinal bleeding there were 39 drugs for which an association with a RR ≥4, if present, could be investigated. The corresponding number of drugs was eight for a rare event like anaphylactic shock.Conclusion: Drug use in children is rare and shows little variation. The number of drugs with enough exposure to detect rare adverse events in children and adolescents within an EHR‐based surveillance system such as EU‐ADR is limited. Use of additional sources of paediatric drug exposure information and global collaboration are imperative in order to optimize EHR data for paediatric safety surveillance.

10 May 2022 in European Journal of General Practice
Verified
Journal Article
Open access
GBGuus C. G. H. Blok
Guus C. G. H. Blok
ENEelke D. Nikkels
Eelke D. Nikkels
JLJohan van der Lei
Johan van der Lei
MBMarjolein Y. Berger
Marjolein Y. Berger
GHGea A. Holtman
Gea A. Holtman
The diagnostic value of C-reactive protein (CRP) for appendicitis in children has not been evaluated in primary care. As biochemical responses and differential diagnoses vary with age, separate eva...

29 December 2023 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
VPVictor Pera
Victor Pera
FVFrauke van Vaerenbergh
Frauke van Vaerenbergh
JKJan A. Kors
Jan A. Kors
Erik MulligenErik Mulligen
Erik Mulligen
RPRowan Parry
Rowan Parry
KVKatia M. C. Verhamme
Katia M. C. Verhamme
Background: Medication errors (MEs) are a major public health concern which can cause harm and financial burden within the healthcare system. Characterizing MEs is crucial to develop strategies to mitigate MEs in the future.Objectives: To characterize ME‐associated reports, and investigate signals of disproportionate reporting (SDRs) on MEs in the Food and Drug Administration's Adverse Event Reporting System (FAERS).Methods: FAERS data from 2004 to 2020 was used. ME reports were identified with the narrow Standardised Medical Dictionary for Regulatory Activities® (MedDRA®) Query (SMQ) for MEs. Drug names were converted to the Anatomical Therapeutic Chemical (ATC) classification. SDRs were investigated using the reporting odds ratio (ROR).Results: In total 488 470 ME reports were identified, mostly (59%) submitted by consumers and mainly (55%) associated with females. Median age at time of ME was 57 years (interquartile range: 37–70 years). Approximately 1 out of 3 reports stated a serious health outcome. The most prevalent reported drug class was “antineoplastic and immunomodulating agents” (25%). The most common ME type was “incorrect dose administered” (9%). Of the 1659 SDRs obtained, adalimumab was the most common drug associated with MEs, noting a ROR of 1.22 (95% confidence interval: 1.21–1.24).Conclusion: This study offers a first of its kind characterization of MEs as reported to FAERS. Reported MEs are frequent and may be associated with serious health outcomes. This FAERS data provides insights on ME prevention and offers possibilities for additional in‐depth analyses.